Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17224067 | 1.00 | EPHA2 (0.44) | EPHA2USP2SMN1; SMN2RECQLMALT1 | |
| SCHEMBL30373604 | 0.89 | GPR119 (0.43) | USP2SMN1; SMN2RECQLMALT1USP30 | |
| SCHEMBL18489091 | 0.87 | NR1H2 (0.41) | EPHA2USP2SMN1; SMN2RECQLMALT1 | |
| SCHEMBL30373606 | 0.87 | GRIN2B (0.41) | USP2SMN1; SMN2RECQLMALT1USP30 | |
| SCHEMBL17234418 | 0.87 | NR1H2 (0.41) | EPHA2USP2SMN1; SMN2RECQLMALT1 | |
| SCHEMBL17224078 | 0.86 | USP2 (0.43) | EPHA2USP2SMN1; SMN2RECQLMALT1 | |
| SCHEMBL31749447 | 0.85 | GPR119 (0.45) | USP2SMN1; SMN2MALT1USP30GPR119 | |
| SCHEMBL29628538 | 0.83 | FPR2 (0.38) | EPHA2USP30GPR119HPGDSRORC | |
| SCHEMBL1993504 | 0.82 | RORC (0.49) | EPHA2USP2SMN1; SMN2RECQLUSP30 | |
| SCHEMBL503531 | 0.82 | RORC (0.49) | EPHA2USP2SMN1; SMN2RECQLUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9840501-B2 | Morpholin-pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170044145-A1 | MORPHOLIN-PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-02-16 | — | — | US | disclosed |
| WO-2015165835-A1 | MORPHOLIN-PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044145-A1 | MORPHOLIN-PYRIDINE DERIVATIVES | OPRM1, MC2R, OPRL1 | EPHA2 3025/4885USP2 4606/4885SMN1; SMN2 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.